AstraZeneca plc’s Hold Rating Reaffirmed at Deutsche Bank (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by stock analysts at Deutsche Bank in a report issued on Wednesday. They currently have a GBX 3,950 ($67.28) price objective on the stock. Deutsche Bank’s price objective indicates a potential downside of 10.60% from the stock’s previous close.
AstraZeneca plc (LON:AZN) traded up 1.12% during mid-day trading on Wednesday, hitting GBX 4418.50. The stock had a trading volume of 1,654,257 shares. AstraZeneca plc has a one year low of GBX 3086.50 and a one year high of GBX 5750.00. The stock’s 50-day moving average is GBX 4389.50 and its 200-day moving average is GBX 4059.10. The company’s market cap is £55.717 billion.
A number of other firms have also recently commented on AZN. Analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca plc in a research note on Thursday, June 26th. They now have a GBX 4,400 ($74.94) price target on the stock. Separately, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, June 20th. Finally, analysts at Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, June 20th. They now have a GBX 4,900 ($83.46) price target on the stock. Seven analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 4,003.68 ($68.19).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.